Clinical trials: Smartphone Application
Optic Nerve Disease, Macular Disease
Implementation of the NEDS EyeCTester App
Group 4a and 4b was an FDA trial that showed that patients who have an Amsler grid abnormality on paper, have a similar abnormality on the app.
- Conditions
- Optic Nerve Disease, Macular Disease, Visual Pathway Disorder
- Trial name
- NCT04607369
- Testing
- EyeCTester
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Neuro-Eye Diagnostic Systems, LLC
Cognitive Impairment, Alzheimer Disease
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
The clinical evaluation of a patient with a cognitive complaint requires neuropsychological tests, evaluating the integrity of memory and other cognitive functions.
- Trial name
- MemScreen (NCT03811184)
- Testing
- MemScreen
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MemScreen
Hemophilia
Hemophilia Mobile App Usability Pilot
The purpose of this study is to evaluate the utility and user experience of a smart phone app for people with medical conditions, used in conjunction with an ActiGraph wearable device and a connected scale.
- Trial name
- NCT03168685
- Testing
- SureSource Engage application
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Healthcare Innovation Technology Lab
Early-Onset Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with…
- Trial name
- NCT05231785
- Testing
- ALN-APP
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Alnylam Pharmaceuticals
Dementia, Alzheimer Disease
The BRAIN App (Phase 2 SBIR)
There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S.
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT06298474
- Testing
- The BRAIN App
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Hopeful Aging